MY FAV PUBLICATIONS IN 2016 MY FOL PUBLICATIONS IN 2016 Prof. Marcelo Carneiro, MD, ID, MSc, PhD

CCIH - Hospital Santa Cruz – SCS – RS Curso de Medicina – UNISC Brazil

- Clostridium spp.

- Influenza vs Antibiotic Stewardship

- MRSA/VRE vs CHG vs Mupirocin

- ITU vs Unncessary urine cultures vs Antimicrobial

- Antimicrobial Resistance vs Stewardship

- Nosocomial Tuberculosis

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

- Clostridium spp.

- Influenza vs Antibiotic Stewardship

- MRSA/VRE vs CHG vs Mupirocin

- ITU vs Unncessary urine cultures vs Antimicrobial

- Antimicrobial Resistance vs Stewardship

- Nosocomial Tuberculosis

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

RESEARCH ARTICLE

Epidemiology and Microbiologic Characterization of Nosocomial Candidemia from a Brazilian National Surveillance Program

André Mario Doi¹, Antonio Carlos Campos Pignatari¹, Michael B. Edmond⁴, Alexandre Rodrigues Marra², Luis Fernando Aranha Camargo³, Ricardo Andreotti Siqueira¹, Vivian Pereira da Mota⁵, Arnaldo Lopes Colombo¹*

 Department of Medicine, Division of Infectious Diseases, Universidade Federal de São Paulo, São Paulo, SP, Brazil, 2 Division of Medical Practice, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil, 3 Instituto Israelita de Ensino e Pesquisa Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil,
Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, United States of America, 5 Laboratório Central, Hospital São Paulo, São Paulo, SP, Brazil BRSCOPE 16 hospitals - RS (2)

2563 BSI (2007-2010)

Prevalence Candidemia = 5,6%

PLOS ONE | DOI:10.1371/journal.pone.0146909 January 25, 2016

Brazil

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

Resistence = 34% (Fluconazol) C. glabrata C. krusei

RF Candidemia not albicans:

- **C**a
- CVC
- PNT
- Neutropenia

Parameters	No
Demographics	
Male	71 (51.8%)
Age (median)	56 y.o
Hospitalization	
Time to candidemia*	29 days
ICU admission**	88 (64.2%)
ICU at the time of candidemia	64 (46.7%)
Underlying Conditions	
Malignancy	44 (32.1%)
Gastrointestinal	26 (18.9%)
Neurologic	11 (8.0%)
Respiratory	9 (6.5%)
Renal	9 (6.5%)
Hepatic	8 (5.8%)
Cardiovascular	7 (5.1%)
Trauma	6 (4.3%)
Transplantation (solid organ)	5 (2.9%)
Transplantation (bone marrow)	2 (1.4%)

*Time to candidemia: time from hospital admission to first culture positive for Candida spp.

** ICU—Intensive Care Unit.

PLOS ONE | DOI:10.1371/journal.pone.0146909 January 25, 2016

Brazil

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

Prof. Marcelo Carneiro, MD, PhD HSC - UNISC

Table 1. Demographics and clinical characteristics of the 137 patients with *Candida* spp. monomicrobial nosocomial bloodstream infections.

Mortality > contries of Northern Hemisphere

	Total (137)	ICU *(64)	Non ICU (73)	Private Hospital * *(28)	Non-private Hospital (109)
Crude Mortality	72.2% (99)	85.0% (55)	53.0% (39)	75.0% (21)	66.9% (73)

Mortality – main hypotheses

- Age (>56 y and < 12 y)
- Ca (32,1%)
- UTI 47% APACHE High

- Late diagnosis
- Sub-optimal treatment (fluconazol)
- Without focus control

PLOS ONE | DOI:10.1371/journal.pone.0146909 January 25, 2016

Brazil

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

- Clostridium spp.

- Influenza vs Antibiotic Stewardship

- MRSA/VRE vs CHG vs Mupirocin

- ITU vs Unncessary urine cultures vs Antimicrobial

- Antimicrobial Resistance vs Stewardship

- Nosocomial Tuberculosis

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

- Clostridium spp.

- Influenza vs Antibiotic Stewardship

- MRSA/VRE vs CHG vs Mupirocin

- ITU vs Unncessary urine cultures vs Antimicrobial

- Antimicrobial Resistance vs Stewardship

- Nosocomial Tuberculosis


MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

Transmission of *Clostridium difficile* During Hospitalization for Allogeneic Stem Cell Transplant

Mini Kamboj, MD;^{1,2,3} Anna Sheahan, PhD;¹ Janet Sun, BS;¹ Ying Taur, MD, MPH;^{2,3} Elizabeth Robilotti, MD, MPH;^{1,2,3} Esther Babady, PhD;⁴ Genovefa Papanicolaou, MD;^{2,3} Ann Jakubowski, MD, PhD;^{3,5} Eric Pamer, MD;^{2,3} Kent Sepkowitz, MD^{1,2,3}

INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY JANUARY 2016, VOL. 37, NO. 1

Most cases of CDI after stem cell transplant represent delayed onset disease in non symptomatic carriers. Transmission on stem cell transplant unit was confirmed in 19% of early CDI cases in our cohort with a probable donor source established in half of the cases.



USA

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

Transmission of *Clostridium difficile* During Hospitalization for Allogeneic Stem Cell Transplant

Mini Kamboj, MD;^{1,2,3} Anna Sheahan, PhD;¹ Janet Sun, BS;¹ Ying Taur, MD, MPH;^{2,3} Elizabeth Robilotti, MD, MPH;^{1,2,3} Esther Babady, PhD;⁴ Genovefa Papanicolaou, MD;^{2,3} Ann Jakubowski, MD, PhD;^{3,5} Eric Pamer, MD;^{2,3} Kent Sepkowitz, MD^{1,2,3}

INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY JANUARY 2016, VOL. 37, NO. 1

Most cases of CDI after stem cell transplant represent delayed onset disease in non symptomatic carriers. Transmission on stem cell transplant unit was confirmed in 19% of early CDI cases in our cohort with a probable donor source established in half of the cases.

Clostridium difficile—To Test or Not to Test?

Anna-Rose Prior, MB, MRPCI, FRCPath;^{1,2} Fidelma Fitzpatrick, MD, BA(Mod), FRCPI, FRCPath^{1,2} Ireland

INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY MARCH 2016, VOL. 37, NO. 3



USA

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

Clostridium difficile—To Test or Not to Test?

Anna-Rose Prior, MB, MRPCI, FRCPath;^{1,2} Fidelma Fitzpatrick, MD, BA(Mod), FRCPI, FRCPath^{1,2}

INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY MARCH 2016, VOL. 37, NO. 3

C. difficile laboratory results are used not only to manage patients with CDI but also to minimize C. difficile transmission risk, we argue that delaying specimen acquisition until the patient has had \geq 3 episodes of diarrhea in 24 hours increases the risk of C. difficile transmission.

Ireland

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

Clostridium difficile—To Test or Not to Test?

Anna-Rose Prior, MB, MRPCI, FRCPath;^{1,2} Fidelma Fitzpatrick, MD, BA(Mod), FRCPI, FRCPath^{1,2}

INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY MARCH 2016, VOL. 37, NO. 3

"Test all with risk factors independent of the number of episodes of diarrhea."

Ireland

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

Transmission of *Clostridium difficile* During Hospitalization for Allogeneic Stem Cell Transplant

Mini Kamboj, MD;^{1,2,3} Anna Sheahan, PhD;¹ Janet Sun, BS;¹ Ying Taur, MD, MPH;^{2,3} Elizabeth Robilotti, MD, MPH;^{1,2,3} Esther Babady, PhD;⁴ Genovefa Papanicolaou, MD;^{2,3} Ann Jakubowski, MD, PhD;^{3,5} Eric Pamer, MD;^{2,3} Kent Sepkowitz, MD^{1,2,3}

INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY JANUARY 2016, VOL. 37, NO. 1

Most cases of CDI after stem cell transplant represent delayed onset disease in non symptomatic carriers. Transmission on stem cell transplant unit was confirmed in 19% of early CDI cases in our cohort with a probable donor source established in half of the cases.

INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY JANUARY 2016, VOL. 37, NO. 1
C O M M E N T A R Y
Clostridium difficile: The More We Learn, the Less We Know
Virginia R. Roth Canada

USA

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

Clostridium difficile: The More We Learn, the Less We Know

Virginia R. Roth

"Acquisition is traditionally thought to involve the ingestion of spores from the contaminated healthcare environment by patients whose normal bowel flora is altered by antibiotics. While the majority of these patients remain asymptomatic, some develop diarrhea, further contaminating the environment and serving as a source of ongoing transmission. "

INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY JANUARY 2016, VOL. 37, NO. 1

Canada

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

Efficacy of Oral Vancomycin in Preventing Recurrent *Clostridium difficile* Infection in Patients Treated With Systemic Antimicrobial Agents

Nicholas W. Van Hise,¹ Alex M. Bryant,² Erin K. Hennessey,^{2,4} Andrew J. Crannage,^{2,4} Jad A. Khoury,³ and Farrin A. Manian⁵

CID 2016:63 (1 September)

The incidence of C. difficile infection was significantly lower in patients receiving prophylaxis (4.2% vs 26.6% in those without prophylaxis; odds ratio, 0.12; 95% confidence interval, .04-.4; P < .001). Prospective studies are needed to better define the risks and benefits of OVP in this vulnerable patient population.

USA

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

- Clostridium spp.

- Influenza vs Antibiotic Stewardship

- MRSA/VRE vs CHG vs Mupirocin

- ITU vs Unncessary urine cultures vs Antimicrobial

- Antimicrobial Resistance vs Stewardship

- Nosocomial Tuberculosis

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

- Clostridium spp.

- Influenza vs Antibiotic Stewardship

- MRSA/VRE vs CHG vs Mupirocin

- ITU vs Unncessary urine cultures vs Antimicrobial

- Antimicrobial Resistance vs Stewardship

- Nosocomial Tuberculosis

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

ORIGINAL ARTICLE

Antibiotic Utilization and Opportunities for Stewardship Among Hospitalized Patients With Influenza Respiratory Tract Infection

Islam M. Ghazi, PharmD;¹ David P. Nicolau, PharmD;^{1,2} Michael D. Nailor, PharmD;^{3,4} Jaber Aslanzadeh, PhD;⁵ Jack W. Ross, MD;² Joseph L. Kuti, PharmD¹

Retrospectively studied – 322 adults (2012-2014) Influenza respiratory tract infections 65,5% use antimicrobial

USA

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

 In a p p r o p r i a t e antibiotic duration (IAD) was defined as antibiotic use for >24 hours after a positive influenza test = 34,5% (had a longer length of stay - 6 days)




FIGURE 1. Number of patients treated with antibiotics per number of days in appropriate antibiotic duration versus inappropriate antibiotic duration groups.

INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY MAY 2016, VOL. 37, NO. 5

USA

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

Outcome	Total cohort (N = 322)	No Antibiotics on Admission (N = 111; 34.4%)	Appropriate Antibiotic Duration (N = 138; 42.8%)	Inappropriate Antibiotic Duration (N = 73; 22.7%)	P Value
Mortality	11 (3.4)	2 (1.8)	6 (4.3)	3 (4.1)	.510
Time to temperature normalization, median d (IQR)	1 (1–2)	1 (1–2)	1 (1–2)	1 (1–2)	.373
Time to WBC normalization, median d (IQR)	2 (1–3)	1 (1–1.5)	2 (1-4.25)	2 (1–3.75)	.050
LOS, median d (IQR)	5 (3–7)	4 (3–6)	5 (3-8)	6 (4–9)	<.001 ^a
Discharge status					
Home	218 (70.1)	83 (74.7)	91 (65.9)	44 (60.2)	.154
Health care	93 (29.9)	26 (23.4)	41 (24.7)	26 (35.6)	
30-day readmission	40 (12.4)	11 (9.9)	21 (15.2)	9 (12.3)	.455
Total hospital cost, median \$ (IQR)	7,553 (5,002–13,077)	5,961 (4,711–9,575)	7,479 (4,866–12,922)	10,645 (6,485–18,035)	<.001 ^a
Hospital net revenue, median \$ (IQR) ^b	2,214 (-2,091-4,623)	2,202 (-507-4,342)	2,957 (-1,616-6,439)	881 (-4,892-3,196)	<.001 ^a

TABLE 2. Clinical and Economic Outcomes by No Antibiotics on Admission Versus Appropriate Antibiotic Duration Versus Inappropriate Antibiotic Duration

- Median loss in net hospital revenue of \$ 2.076/IAD

- Mortality was similar.

INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY MAY 2016, VOL. 37, NO. 5

USA

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

- Clostridium spp.

- Influenza vs Antibiotic Stewardship

- MRSA/VRE vs CHG vs Mupirocin

- ITU vs Unncessary urine cultures vs Antimicrobial

- Antimicrobial Resistance vs Stewardship

- Nosocomial Tuberculosis

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

- Clostridium spp.

- Influenza vs Antibiotic Stewardship

- MRSA/VRE vs CHG vs Mupirocin

- ITU vs Unncessary urine cultures vs Antimicrobial

- Antimicrobial Resistance vs Stewardship

- Nosocomial Tuberculosis

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

ORIGINAL ARTICLE


Prevalence of *qacA/B* Genes and Mupirocin Resistance Among Methicillin-Resistant *Staphylococcus aureus* (MRSA) Isolates in the Setting of Chlorhexidine Bathing Without Mupirocin

David K. Warren, MD, MPH;¹ Martin Prager, MD;¹ Satish Munigala, MBBS, MPH;¹ Meghan A. Wallace, BS;² Colleen R. Kennedy;² Kerry M. Bommarito, PhD;¹ John E. Mazuski, MD, PhD;³ Carey-Ann D. Burnham, PhD²

To determine the frequency of qacA/B chlorhexidine tolerance genes and highlevel mupirocin resistance among MRSA isolates before and after the introduction of a chlorhexidine (CHG) daily bathing intervention in a surgical intensive care unit.


USA

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016



USA

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016



MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

qacA/B Status			
	qacA/B(+) MRSA,	qacA/B(-) MRSA,	
	No. (%) $(n = 36)$	No. (%) $(n = 468)$	<i>P</i> Value
mupA(+)	9 (25)	26 (5.6)	.003
mupA(-)	27 (75)	442 (94.4)	
<i>SCCmec</i> type			
Ι	2 (5.5)	8 (1.7)	.15
II	18 (50.0)	287 (61.4)	.21
III	0	3 (0.6)	.00
IV	15 (41.7)	169 (36.1)	.59
V	1 (2.8)	1 (0.2)	.13

TABLE 3. Comparison of MRSA Isolate Characteristics

by

INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY MAY 2016, VOL. 37, NO. 5

USA

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

This change in the frequency of qacA/B genes is most likely due to patients in those years being exposed in prior admissions.




FIGURE 2. Prevalence of qacA/B(+) among sampled MRSA nasal isolates, per year (2005–2012). MRSA, methicillin-resistant *S. aureus*; p, *P* value.

INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY MAY 2016, VOL. 37, NO. 5

USA

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

CONCLUSIONS

- Prevalence of qacA/B associated with chlorhexidine tolerance did change over time among colonizing MRSA isolates over the 8-year period of daily patient bathing with chlorhexidine soap;
- Further studies are needed to determine whether other ICU-based decolonization strategies, such as universal treatment with chlorhexidine and intranasal mupirocin, will result in selection of co-resistant isolates.

INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY MAY 2016, VOL. 37, NO. 5

USA

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

- Clostridium spp.

- Influenza vs Antibiotic Stewardship

- MRSA/VRE vs CHG vs Mupirocin

- ITU vs Unncessary urine cultures vs Antimicrobial

- Antimicrobial Resistance vs Stewardship

- Nosocomial Tuberculosis

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016


Evaluation of a Novel Intervention to Reduce Unnecessary Urine Cultures in Intensive Care Units at a Tertiary Care Hospital in Maryland, 2011–2014

Lauren Epstein, MD, MSc;^{1,2} Jonathan R. Edwards, Mstat;¹ Alison Laufer Halpin, PhD;¹ Michael Anne Preas, RN, BSN, CIC;³ David Blythe, MD, MPH;⁴ Anthony D. Harris, MD, MPH;⁵ David Hunt, MSN, MBA, RN;³ J. Kristie Johnson, PhD;⁵ Mala Filippell, RN, BSN, CIC;³ Carolyn V. Gould, MD, MSc;¹ Surbhi Leekha, MBBS, MPH⁵

Infect Control Hosp Epidemiol 2016;37:606–609

USA


MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016



Infect Control Hosp Epidemiol 2016;37:606–609

USA

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016



Infect Control Hosp Epidemiol 2016;37:606–609

USA

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016




FIGURE 3. Predicted catheter-associated urinary tract infection (CAUTI) rates in 5 intensive care units in relation to hospital interventions, July 1, 2011–March 31, 2014. CAUTI rates at the beginning of the preintervention period differed significantly among the 5 intensive care unit locations; therefore, each unit is shown individually. CUSP, Comprehensive Unit-based Safety Program.

Infect Control Hosp Epidemiol 2016;37:606–609

USA

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

Evaluation of a Novel Intervention to Reduce Unnecessary Urine Cultures in Intensive Care Units at a Tertiary Care Hospital in Maryland, 2011–2014

These findings also hint at a broader question of whether test ordering practices can be modified to optimize test performance and patient outcomes. Assessing the impact of laboratory-based interventions on other outcomes such as antimicrobial use will inform future interventions.

Infect Control Hosp Epidemiol 2016;37:606–609

USA

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

- Clostridium spp.

- Influenza vs Antibiotic Stewardship

- MRSA/VRE vs CHG vs Mupirocin

- ITU vs Unncessary urine cultures vs Antimicrobial

- Antimicrobial Resistance vs Stewardship

- Nosocomial Tuberculosis

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

- Clostridium spp.

- Influenza vs Antibiotic Stewardship

- MRSA/VRE vs CHG vs Mupirocin

- ITU vs Unncessary urine cultures vs Antimicrobial


- Antimicrobial Resistance vs Stewardship

- Nosocomial Tuberculosis

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

Polymyxin B Resistance in Carbapenem-Resistant *Klebsiella pneumoniae*, São Paulo, Brazil

Flávia Bartolleti, Bruna Mara Silva Seco, Carla Capuzzo dos Santos, Carolina Bragança Felipe, Mara Elisa Borsato Lemo, Tatiane da Silva Alves, Lilian F. Passadore, Marcelo J. Mimica, Suely Carlos Ferreira Sampaio, Alexandre Prehn Zavascki, Jorge Luiz Mello Sampaio




Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 22, No. 10, October 2016

Brazil

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

Polymyxin B Resistance in Carbapenem-Resistant *Klebsiella pneumoniae*, São Paulo, Brazil

Flávia Bartolleti, Bruna Mara Silva Seco, Carla Capuzzo dos Santos, Carolina Bragança Felipe, Mara Elisa Borsato Lemo, Tatiane da Silva Alves, Lilian F. Passadore, Marcelo J. Mimica, Suely Carlos Ferreira Sampaio, Alexandre Prehn Zavascki, Jorge Luiz Mello Sampaio




Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 22, No. 10, October 2016

Brazil

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

Polymyxin B Resistance in Carbapenem-Resistant *Klebsiella pneumoniae*, São Paulo, Brazil

Flávia Bartolleti, Bruna Mara Silva Seco, Carla Capuzzo dos Santos, Carolina Bragança Felipe, Mara Elisa Borsato Lemo, Tatiane da Silva Alves, Lilian F. Passadore, Marcelo J. Mimica, Suely Carlos Ferreira Sampaio, Alexandre Prehn Zavascki, Jorge Luiz Mello Sampaio



Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 22, No. 10, October 2016

Brazil

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

Review

Antimicrobial resistance in Enterobacteriaceae in Brazil: focus on β -lactams and polymyxins

Jorge Luiz Mello Sampaio^{a,b,*}, Ana Cristina Gales^{c,*}

brazilian journal of microbiology 47S (2016) 31–37

- During the last 30 years there has been a dissemination of plasmid-mediated B-lactamases in Enterobacteriaceae in Brazil.
- Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae became widely disseminated in Brazil during the last decade and KPC production is currently the most frequent resistance mechanism (96.2%) in carbapenem resistant K. pneumoniae.

Brazil

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis

Emelie C Schuts, Marlies E J L Hulscher, Johan W Mouton, Cees M Verduin, James W T Cohen Stuart, Hans W P M Overdiek, Paul D van der Linden, Stephanie Natsch, Cees M P M Hertogh, Tom F W Wolfs, Jeroen A Schouten, Bart Jan Kullberg, Jan M Prins

Lancet Infect Dis. 2016 Jul;16(7):847-856.

Antimicrobial stewardship is advocated to improve the quality of antimicrobial use. We did a systematic review and meta-analysis to assess whether antimicrobial stewardship objectives had any effects in hospitals and long-term care facilities on four predefined patients' outcomes: clinical outcomes, adverse events, costs, and bacterial resistance rates.

Netherlands

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

	Experimental		Control		Weight		Odds ratio (95%
	Events	Total	Events	Total			
Arnold et al (2009)	82	975	121	660	5.5%	_ # _	0.41 (0.30-0.55
Asadi et al (2013)	231	2506	90	697	5.7%		0.68 (0.53-0.89
Baudel et al (2009)	4	73	4	9	1.1% -	.	0.07 (0.01-0.38
Blasi et al (2008)	107	1092	234	1755	5.8%		0.71 (0.55-0.90
Dambrava et al (2009)	20	531	13	111	3.4%		0.30 (0.14-0.61
Dean et al (2006)	0	0	0	0			Not estimable
Diaz et al (2003)	21	196	12	245	3.3%	_	2.33 (1.12-4.86
Ewig et al (2000)	10	170	5	62	2.1%		0.71 (0.23-2.17
Ferrer et al (2010)	59	160	49	116	4.5%		0.80 (0.49-1.30
Frei et al (2006)	6	53	6	25	1.8%	_	0.40 (0.12-1.41
Frei et al (2010)	11	357	19	274	3.2%	_	0.43 (0.20-0.91
Galayduyk et al (2008)	30	381	12	50	3.3%	_	0.27 (0.13-0.57
Garcia et al (2007)	49	96	40	69	3.8%	_	0.76 (0.41-1.41
Grenier et al (2011)	86	1557	109	1097	5.6%		0.53 (0.39-0.71
Horn et al (2007)	57	262	13	99	3.7%		1.84 (0.96-3.53
Huijts et al (2013)	0	947	0	89			Not estimable
Huvent-Grelle et al (2004) 17	64	11	48	2.8%	_	1.22 (0.51–2.91
Kett et al (2011)	84	129	137	174	4-4%	_	0.50 (0.30-0.84
Malone et al (2001)	0	279	0	51			Not estimable
Marras et al (1998)	24	201	7	51	2.7%	_	0.85 (0.35-2.11
Marras et al (2004)	34	386	4	32	2.1%	_	0.68 (0.22-2.04
Maxwell et al (2005)	2	124	23	567	1.4%	_	0.39 (0.09-1.67
Menendez et al (2002)	24	259	7	36	2.6%	_	0.42 (0.17-1.07
Menendez et al (2005)	52	960	22	245	4.4%		0.58 (0.35-0.98
Menendez et al (2007)	19	190	11	81	3.1%	-	0.71 (0.32–1.56
Miletin et al (2001)	8	37	7	38	2.0%		1.22 (0.39-3.80
Mortensen et al (2004)	20	323	21	97	3.7%	_	0.24 (0.12-0.46
Pradelli et al (2014)	35	847	37	1370	4.6%		1.55 (0.97-2.49
Reyes et al (2007)	26	325	9	100	3.1%		0.88 (0.40-1.9
Sakaguchi et al (2013)	4	16	17	69	1.7%		1.02 (0.29-3.58
Silveira et al (2012)	0	66	0	46			Not estimable
Spoorenberg et al (2014)	17	762	11	402	3.2%	_	0.81 (0.38-1.75
Triantafyllidis et al (2012)	14	152	17	100	3.2%		0.50 (0.23-1.06
Wilke et al (2011)	10	44	7	38	2.1%		1-30 (0-44-3-84
Total (95% CI)		13228		8717	100.0%	•	0.65 (0.54-0.8
Total events	1163		1075			-	
					0.005	0.1 1 10	:
Heterogeneity: τ ² =0·15; χ ²	0	df_20 (n	.0.00001	D CEN		Favours experimental Favours contro	

Guideline-adherent empirical therapy was associated with a RR reduction for mortality of 35% (RR 0.65, 95% CI 0.54– 0.80, p<0.0001) and for deescalation of 66% (RR 0.44, 0.30–0.66, p<0.0001).

Figure 2: Effect on mortality of prescribing empirical antimicrobial therapy according to guidelines

Lancet Infect Dis. 2016 Jul;16(7):847-856.

Netherlands

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016




Figure 4: Effect of bedside consultation for Staphylococcus aureus bacteraemia on mortality

Lancet Infect Dis. 2016 Jul;16(7):847-856.

Netherlands

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

	Experimental		Contro	I	Weight		Odds ratio (95% C
	Events	Total	Events	Total			
Bootman et al (1979)	0	66	3	39	3.0%		0.08 (0.00-1.56)
Burton et al (1991)	7	75	4	72	10.2%		1.75 (0.49-6.25)
Destache et al (1989)	2	23	5	23	6.9%		0.34 (0.06–1.99)
Destache et al (1990)	6	75	10	70	12.1%	_	0.52 (0.18–1.52)
Dillon et al (1989)	3	48	1	34	4.6%		2·20 (0·22–22·10)
Fernandez de Gatta et al (199	6) 5	37	14	33	11.1%	_	0.21 (0.07-0.68)
Hoffa et al (1989)	0	49	6	88	3.2%		0.13 (0.01-2.33)
lwamoto et al (2003)	0	0	0	0			Not estimable
Karam et al (1991)	16	85	15	86	15.2%	e	1.10 (0.50-2.39)
Leehey et al (1993)	13	80	12	74	14.3%		1.00 (0.43-2.36)
Leon-Dijan et al (2011)	0	56	4	47	3.1%	_	0.09 (0.00-1.63)
Sveska et al (1985)	0	0	0	0			Not estimable
Van Lent-Evers et al (1999)	1	48	7	62	5.2%	_	0.17 (0.02-1.41)
Welty et al (1994)	4	61	13	55	10.9%	-	0.23 (0.07–0.74)
Total (95% CI)		703		683	100.0 %		0.50 (0.29-0.88)
Total events	57		94			•	
						0.1 10	100
Heterogeneity: τ²=0·38; γ²=1	9∙83. df=11	L (ɒ=0·0¤	5); /²=45%				•
Test for overall effect: Z=2·42		V 3	.,, 13.4			Favours experimenta Favours cor	ntrol

Figure 3: Effect of therapeutic drug monitoring on the rate of nephrotoxicity

Evidence of effects was less clear for adjusting therapy according to renal function, discontinuing therapy based on lack of clinical or microbiological evidence of infection, and having a local antibiotic guide.

Lancet Infect Dis. 2016 Jul;16(7):847-856.

Netherlands

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

Review

Antimicrobial resistance in Enterobacteriaceae in Brazil: focus on β -lactams and polymyxins

Jorge Luiz Mello Sampaio^{a,b,*}, Ana Cristina Gales^{c,*}

BRAZILIAN JOURNAL OF MICROBIOLOGY 47S (2016)31–37

- Polymyxin B resistance in KPC-2-producing K. pneumoniae has come to an alarming rate of 27.1% in 2015 in São Paulo, the largest city in Brazil.
- New Delhi metallo-B-lactamase was detected in Brazil in 2013, has been reported in different Brazilian states but are not widely disseminated.
- Antimicrobial resistance in Enterobacteriaceae in Brazil is a very serious problem that needs urgent actions which includes both more strict adherence to infection control measures and more judicious use of antimicrobials.

Brazil

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

Antimicrobial Stewardship: A Call to Action for Surgeons

Massimo Sartelli,¹ Therese M. Duane,² Fausto Catena,³ Jeffrey M. Tessier,⁴ Federico Coccolini,⁵ Lillian S. Kao,⁶ Belinda De Simone,³ Francesco M. Labricciosa,⁷ Addison K. May,⁸ Luca Ansaloni,⁵ and John E. Mazuski⁹

> SURGICAL INFECTIONS Volume 17, Number 6, 2016

> > Review

"Surgeons: Hear your call. It is your time to participate and your time to lead. Now is the time to act!"

Italy

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

- Candidemia

- Clostridium spp.

- Influenza vs Antibiotic Stewardship

- MRSA/VRE vs CHG vs Mupirocin

- ITU vs Unncessary urine cultures vs Antimicrobial

- Antimicrobial Resistance vs Stewardship

- Nosocomial Tuberculosis

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

- Candidemia

- Clostridium spp.

- Influenza vs Antibiotic Stewardship

- MRSA/VRE vs CHG vs Mupirocin

- ITU vs Unncessary urine cultures vs Antimicrobial

- Antimicrobial Resistance vs Stewardship

- Nosocomial Tuberculosis

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

Protecting Our Front-liners: Occupational Tuberculosis Prevention Through Infection Control Strategies

У

Sabine Verkuijl¹ and Keren Middelkoop^{2,3}

Clinical Infectious Diseases[®] 2016;62(S3):S231–7

"HCWs are on the front lines of care—and on the front lines of risk. We must also be on the front lines of change"

South Africa

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

Protecting Our Front-liners: Occupational Tuberculosis Prevention Through Infection Control Strategies

Sabine Verkuijl¹ and Keren Middelkoop^{2,3}

Clinical Infectious Diseases[®]

2016;62(S3):S231-7




Table 1. Fears Expressed by Healthcare Workers in Drug-Resistant **Tuberculosis Hospital Wards**

Working Environment HCWs' Own Well-being Developing MDR or XDR tuberculosis Treatment course Patients' behavior (including the Lack of particulate injections, long period

- of hospitalization, and side effects such as hearing loss)
- Lack of psychosocial support (including stigma)
- Poor treatment outcomes
- Dying

- Well-being of Family/ Dependents
- Infecting family members
- Family managing without them should they be ill, be hospitalized, or die
- Financial implications (the lack of compensation)
- Lack of psychosocial support for the family (including stigma)

South Africa

Inadequate

respirators

infection control

implementation

Stigma should they

develop MDR or

XDR tuberculosis

MY FAVORITE INFECTION CONTROL PUBLICATIONS IN 2016

